572 related articles for article (PubMed ID: 3286577)
1. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
Engelhard D; Morag A; Or R; Naparstek E; Cividalli G; Ruchlemer R; Aker M; Maayan S; Slavin S
Isr J Med Sci; 1988 Mar; 24(3):145-50. PubMed ID: 3286577
[TBL] [Abstract][Full Text] [Related]
2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
3. Acyclovir prophylaxis in bone marrow transplant recipients.
Lundgren G; Wilczek H; Lönnqvist B; Lindholm A; Wahren B; Ringdén O
Scand J Infect Dis Suppl; 1985; 47():137-44. PubMed ID: 3006228
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
5. Low-dose oral acyclovir for prevention of herpes simplex virus infection during OKT3 therapy.
Tang IY; Maddux MS; Veremis SA; Bauma WD; Pollak R; Mozes MF
Transplant Proc; 1989 Feb; 21(1 Pt 2):1758-60. PubMed ID: 2652575
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
Trigg ME; Billing R; Sondel PM; Exten R; Hong R; Bozdech MJ; Horowitz SD; Finlay JL; Moen R; Longo W
Cancer Treat Rep; 1985 Apr; 69(4):377-86. PubMed ID: 3888387
[TBL] [Abstract][Full Text] [Related]
8. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).
Kedar E; Or R; Naparstek E; Zeira E; Slavin S
Bone Marrow Transplant; 1988 Mar; 3(2):129-40. PubMed ID: 3048477
[TBL] [Abstract][Full Text] [Related]
9. Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT.
Verdonck LF; Cornelissen JJ; Smit J; Lepoutre J; de Gast GC; Dekker AW; Rozenberg-Arska M
Bone Marrow Transplant; 1993 Feb; 11(2):177-9. PubMed ID: 8382096
[TBL] [Abstract][Full Text] [Related]
10. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
12. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro.
Ljungman P; Wilczek H; Gahrton G; Gustavsson A; Lundgren G; Lönnqvist B; Ringdén O; Wahren B
Bone Marrow Transplant; 1986 Dec; 1(2):185-92. PubMed ID: 2844333
[TBL] [Abstract][Full Text] [Related]
13. Studies in the prophylaxis of herpes infections in severely immunocompromised patients using acyclovir.
Prentice HG; Hann IM
Schweiz Med Wochenschr Suppl; 1983; 14():26-9. PubMed ID: 6361988
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
15. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
[TBL] [Abstract][Full Text] [Related]
16. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion.
Bunin N; Aplenc R; Iannone R; Leahey A; Grupp S; Monos D; Pierson G
Bone Marrow Transplant; 2005 Feb; 35(4):369-73. PubMed ID: 15640818
[TBL] [Abstract][Full Text] [Related]
17. Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow.
Trigg ME; Sondel PM; Billing R; Finlay JL; Peterson A; Hong R; Frierdich S; Shahidi N
J Biol Response Mod; 1985 Dec; 4(6):602-12. PubMed ID: 3910764
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
